Copyright © 2022 StrategyHelix Inc. All Rights Reserved.
Global Pen Needles Market - Outlook and Forecast 2022-2027
The global market for pen needles, which are attached to durable or prefilled pens used by patients to inject medication, was valued at USD 1.2 billion in 2021. It is projected to reach USD 1.7 billion by 2027, growing at a CAGR of 6.09% from 2022 to 2027. The main users of pen needles are insulin users, growth hormone users, and other self-injecting medication users.
Advancements in needle manufacturing technology have resulted in shorter and thinner needles, reducing needle stick injuries and improving injection comfort. BD (Becton, Dickinson) is a key player in this market and has launched innovative products in the pen needle segment.
|No. of Pages||
USD 1.2 billion in 2020
Product Type, Length, Therapy, and Distribution Channel, and Geography
|No. of Companies Mentioned||
The market growth is primarily driven by the increasing prevalence of diabetes and the demand for self-injection devices. However, factors such as preference for alternative drug delivery methods, poor reimbursement in developing countries, and needle anxiety may restrain market growth. Opportunities lie in the growing preference for biosimilar drugs and emerging markets.
All injector pens require single-use pen needles for each injection. These needles come in various lengths to accommodate different depths of subcutaneous tissue. They are designed for single-use subcutaneous injection and should not be reused. Pen needles typically consist of an outer plastic shell used to attach the needle to the pen and an inner plastic shell that protects the needle. Proper instructions from healthcare professionals are necessary to ensure their correct use.
The prevalence of diabetes is predicted to rise globally due to unhealthy diets and lifestyle choices. Developing countries, particularly low-income countries, are increasingly demanding medication, with patients preferring injector pens. High usage of 8mm syringes and a lack of awareness and education contribute to the higher adoption of insulin pen needles in low-middle income countries.
In contrast to developed countries where only older people are affected by diabetes, developing countries have a higher prevalence among younger children due to childhood obesity. Individuals of adult age and elderly persons above 65 are also prone to diabetes in developing countries. Lifestyle changes contribute to the high incidence of type-II diabetes, with one in 11 adults between the ages of 0-79 affected.
Self-injection devices, especially pens for subcutaneous delivery of biopharmaceuticals, are an expanding segment of drug delivery devices. With the increase in biological drugs and diabetes cases, their significance is expected to grow further. The shift towards self-administration at home to save costs and provide convenience drives the demand for self-injection devices. Self-injection solutions improve the quality of care from the patient’s perspective and allow for better control over timing and reduced risk.
Manufacturers are introducing new pen needles that offer advantages over conventional ones. These next-generation pen needles aim to minimize needle-stick injuries and improve medication adherence. Some manufacturers have successfully improved their traditional pen needle portfolios by incorporating new technologies.
Accidental blood exposures pose a risk of serious infections to healthcare providers (HCPs) and non-healthcare users. Pen needles with automatic protective safety features enable patients to self-administer drugs with assistance while ensuring the safety of HCPs. Safety pen needles (SPNs) have been found to decrease the risk of bloodborne infections without any adverse events. Safety devices are crucial in preventing injuries and infectious agent exposure among healthcare workers. Engineered sharps injury protection systems can prevent over 80% of needle-stick injuries.
The market is segmented based on various factors, including product type, length, therapy, and distribution channel, and geography.
Segmentation by Product Type
Standard Pen Needles
Safety Pen Needles
Segmentation by Length
Segmentation by Therapy
Segmentation by Distribution Channel
Segmentation by Geography
North America – US, Canada
Europe – Germany, France, UK, Italy, Spain
APAC – China, Japan, India, South Korea, Australia
Latin America – Brazil, Mexico, Argentina
Middle East & Africa – South Africa, Saudi Arabia, Turkey
The global pen needles market is categorized into two major product types: standard pen needles and safety pen needles. As of 2021, standard pen needles held the largest market share of 71.72% globally. This can be attributed to their widespread daily usage by diabetic patients requiring larger doses. However, these needles are less preferred due to their higher risk of needle-stick injuries and interference with the safe use of pen needles. Consequently, their demand is expected to decline soon. Factors such as increasing diabetes prevalence and growing awareness of insulin pen usage support the growth of the safety pen needle segment. Technological advancements in this segment and the launch of next-generation products are expected to drive favorable growth, offering the potential to minimize needle-stick injuries to patients.
The needle length segment is divided into short needles and long needles. Short needles accounted for the largest market share of 78.30% in 2021. Among them, 4 mm-sized pen needles are most commonly prescribed to patients, including obese individuals with the target disease. Patients are increasingly opting for the shortest and thinnest needles due to the greater comfort they provide compared to injections. Additionally, their short length facilitates easy access to the subcutaneous tissue of patients.
In terms of therapy, the market is segmented into insulin and non-insulin use. The insulin pen needles market dominated with an 81.20% market share in 2021 and is expected to continue showcasing lucrative growth throughout the forecast period. This growth can be attributed to the increasing awareness and adoption of self-administered insulin therapy among both type 1 and type 2 diabetes patients. In the non-insulin therapy segment, significant growth is anticipated for GLP-1 and growth hormone therapy. These therapies have the capability to effectively lower blood glucose levels in patients with type 2 diabetes.
Based on distribution channels, the global pen needles market is segmented into retail and online channels. The retail segment accounted for the largest share of 76.96% in 2021, with hospitals and clinics playing a major role in distributing pen needles. Retail pharmacies often collaborate with hospitals and clinics to maximize profits, considering them as primary points of contact. On the other hand, online distribution channels are expected to witness substantial growth in the coming years. The COVID-19 pandemic has accelerated the demand for pen needles through online platforms.
Geographically, the Europe region dominates the global market with a share of 33.85%, followed by North America with a share of 29.65%, APAC with 24.90%, Latin America with 7.48%, and the Middle East & Africa region with 6.12% share in the global market.
Key companies profiled in this report include BD, B. Braun Melsungen, Novo Nordisk, Owen Mumford, Ypsomed, AdvaCare Pharma, Allison Medical, ARKRAY, GlucoRx, Hindustan Syringes & Medical Devices, HTL-STREFA, IGAKU NEEDLES, Iyon Medical, Links Medical Products, MedExel, Medivena, Montméd, Narang Medical, Nipro Europe Group Companies, Promisemed Medical Devices, SHANGHAI BERPU MEDICAL, Simple Diagnostics, Terumo Europe, Trividia Health, UltiMed, Van Heek Medical, VOGT MEDICAL.
These key players maintain a significant presence across regions such as Europe, North America, and APAC. Market competition is driven by factors such as product quality, quantity, technology, safety features, and pricing, and it is expected to intensify in the coming years. These companies are strategically focusing on introducing next-generation products to cater to the growing demand for self-injection devices and safety pen needles. Currently, the level of competition in the market is relatively low, as there are only a few key vendors, and the market has not witnessed significant merger and acquisition activities.
For instance, B.Braun Melsungen, one of the prominent vendors, is introducing second-generation needles, while other competitors are also launching safety needles in response to market demand. These safety needles are predominantly adopted in developed countries. The dominant position of European markets, driven by the increasing target population and the adoption of advanced technologies like pen needles, makes the region a focal point for product launches by vendors. While major vendors consistently compete for market leadership, occasional competition arises from local vendors seeking to establish their presence.
Key Questions Answered
WHAT IS THE PROJECTED SIZE OF THE GLOBAL PEN NEEDLE MARKET?
The anticipated size of the global pen needle market is USD 1.7 million by 2027.
WHAT IS THE ANTICIPATED GROWTH RATE OF THE GLOBAL PEN NEEDLE MARKET?
The projected compound annual growth rate (CAGR) of the global pen needle market is 6.09%.
WHO ARE THE MAJOR PARTICIPANTS IN THE GLOBAL PEN NEEDLE MARKET?
The key players in the global pen needle market include BD, B. Braun Melsungen, Novo Nordisk, Owen Mumford, and Ypsomed.
WHAT FACTORS ARE CONTRIBUTING TO THE GROWTH OF THE GLOBAL PEN NEEDLE MARKET?
The growth of the global pen needle market is being driven by factors such as the increasing prevalence of chronic diseases, the demand for safety needles, and the growing preference for e-commerce as a distribution channel.
WHICH REGION IS EXPECTED TO HAVE THE LARGEST MARKET SHARE BY 2027?
Europe is projected to have the largest market share in the pen needle market by 2027.